Hypovitaminosis D is Associated with Greater Body Mass Index and Disease Activity in Pediatric Systemic Lupus Erythematosus

ObjectiveMelanoma-associated antigen gene B2 (MAGE-B2) encodes an embryonic antigen normally silenced after birth except in testis and placenta. We identified the MAGE-B2 gene and autoantibodies in pediatric patients with systemic lupus erythematosus (SLE) glomerulonephritis. We investigated the prevalence of MAGE-B2 autoantibodies in association with active SLE, to determine a pathogenetic role of MAGE-B2 protein through its distribution in cells and tissues.MethodsAcross-sectional study analyzed the frequency of MAGE-B2 autoantibodies in 40 patients with pediatric SLE, 23 adult controls, and 16 patients with pediatric juvenile rheumatoid arthritis (JRA) using Western blots containing recombinant MAGE-B2. SLE Disease Activity Index 2000 (SLEDAI-2K) and British Isles Lupus Assessment Group (BILAG) index measured SLE disease activity. Tissue distribution of MAGE-B2 protein was assessed by immunohistochemistry, immunofluorescence, and Western blots.ResultsSeventeen (43%) of 40 pediatric SLE patients had MAGE-B2 autoantibodies as compared to 0 of 16 JRA patients and 2 of 23 adult controls. SLE disease activity was significantly higher in MAGE-B2 autoantibody-positive versus autoantibody-negative patients (SLEDAI-2K, mean 10.9 vs 5.2, p = 0.013; BILAG, mean 15.3 vs 6.3, p = 0.023). Active nephritis was more prevalent (60% vs 24%) inMAGE-B2 autoantibody-positive than autoantibody-negative SLE patients. MAGE-B2 protein was visualized in SLE kidney proximal convoluted tubules and in tumor epithelial cells, but not in lymphoblastoid cells.ConclusionMAGE-B2 autoantibody appears to be a clinically relevant biomarker for pediatric SLE disease activity and nephritis.

Download Full-text

Body Composition in Iraqi Women With Systemic Lupus Erythematosus

Global Journal of Health Science ◽

10.5539/gjhs.v11n1p63 ◽

2018 ◽

Vol 11 (1) ◽

pp. 63

Author(s):

Faiq I. Gorial ◽

Zainab A. Mahmood ◽

Sundus Al Obaidi

Keyword(s):

Systemic Lupus Erythematosus ◽

Body Mass Index ◽

Body Composition ◽

Social Class ◽

Disease Activity ◽

Lean Mass ◽

Lupus Erythematosus ◽

Disease Duration ◽

Systemic Lupus ◽

Mass Percentage

BACKGROUND & OBJECTIVE: SLE is one of systemic diseases, targeting young patients, so we try to study the one of factors that affected these patients. The aim of our study is to describe the body composition in Iraqi lupus patients, and assess the effect of the disease activity, disease duration, treatment, and patients’ social class in development of sarcopenia. PATIENTS & METHOD: Sixty women, age > 18years with SLE and 56 matched controls were studied. Disease activity measured by systemic lupus erythematosus disease activity index, and functional status measured by systemic lupus erythematosus quality of life questionnaire. Body mass index, waist circumference measured for patients and controls. Body composition analyzed by dual energy absorptiometry x-ray. RESULTS: Mean age for patients was 31.75±10.06 years, and mean disease duration was 19.62±10.76 months. No differences in body mass index, central obesity, lean mass percentage, fat mass percentage, appendicular lean mass index, and bone mineral density between patients and controls. Z score was lower in lupus patients as compared with controls (-1.61±0.8 for patients, -1.26±0.71 for control, p= 0.013). Treatment with azathioprine found to decrease the risk of sarcopenia (p= 0.046). Medical social class and working social class show lower risk for sarcopenia compared to unemployed class (p= 0.003, 0.002 respectively). However disease duration, disease activity, using prednisolone, and functional status had no effect. CONCLUSIONS: No significant differences in body mass index, fat mass percentage, lean mass percentage, and appendicular lean mass index in lupus patients and controls. Lupus patients have higher risk to loss their bone density.

Download Full-text

SYMPTOMATIC COVID INFCETIONS IN ADULT AND PEDIATRIC SYSTEMIC LUPUS ERYTHEMATOSUS AND RELATION TO DISEASE ACTIVITY

10.47660/cbr.2020.17828 ◽

2021 ◽

Author(s):

Simone Appenzeller ◽

Kaik da Silva Gomes ◽

Mariana Moraes da Silva Lucino ◽

Ana Carolina Londe ◽

Diego de Paula Ferreira Nunes ◽

...

Keyword(s):

Systemic Lupus Erythematosus ◽

Disease Activity ◽

Lupus Erythematosus ◽

Systemic Lupus ◽

Pediatric Systemic Lupus Erythematosus

Download Full-text

Pediatric systemic lupus erythematosus. Retrospective analysis of clinico-laboratory parameters and their association with systemic lupus erythematosus disease activity index score

Saudi Medical Journal ◽

10.15537/smj.2018.10.23625 ◽

2018 ◽

Vol 39 (10) ◽

pp. 1060-1060

Author(s):

Suzan Attar

Keyword(s):

Systemic Lupus Erythematosus ◽

Disease Activity ◽

Retrospective Analysis ◽

Lupus Erythematosus ◽

Activity Index ◽

Disease Activity Index ◽

Systemic Lupus Erythematosus Disease ◽

Systemic Lupus ◽

Pediatric Systemic Lupus Erythematosus ◽

Activity Index Score

Download Full-text

SIGLEC1 (CD169) is a sensitive biomarker for the deterioration of the clinical course in childhood systemic lupus erythematosus

Lupus ◽

10.1177/0961203320965699 ◽

2020 ◽

Vol 29 (14) ◽

pp. 1914-1925

Author(s):

Sae Lim von Stuckrad ◽

Jens Klotsche ◽

Robert Biesen ◽

Mareike Lieber ◽

Julia Thumfart ◽

...

Keyword(s):

Systemic Lupus Erythematosus ◽

Disease Activity ◽

Lupus Erythematosus ◽

Clinical Course ◽

Youden Index ◽

Systemic Lupus ◽

Pediatric Systemic Lupus Erythematosus ◽

Elevated Expression ◽

Membrane Bound

Background To analyse the validity of membrane-bound SIGLEC1 (CD169) as a sensitive biomarker for monitoring disease activity in pediatric systemic lupus erythematosus (SLE). Methods 27 children and adolescents with SLE were followed for a mean of 13.5 months. During consecutive routine visits SLEDAI-2k, C3, C4 and ds-DNA values were determined. Additionally, expression of SIGLEC1 on monocytes was determined by flow cytometry. The amount of PE-labelled CD169 mAb bound per monocyte was analyzed using QuantiBRITE™ PE tubes. Associations between biomarkers and the clinical course were investigated by regression analysis. Results In general, SIGLEC1 expression is high on SLE-derived monocytes (mean 6 359 (SD 6 056) molecules/monocyte, cut-off 2 500 molecules/monocyte), all patients with newly diagnosed SLE exhibit elevated expression (mean 13366 (SD 7 750) molecules/monocyte). Changes (Δ) in SIGLEC1 levels during the clinical course is the only biomarker that significantly correlates with the change in SLEDAI-2k (betaST = 0.28, p = 0.001). At follow-up visit, a clinically important worsening was experienced by 47.6% of patients with a Δ SIGLEC1 > 2 151 molecules/cell (OR 5.31) and 72.4% with a Δ SIGLEC1 > 756 molecules/cell (OR 8.90). Conversely, 36.4% of patients with a Δ SIGLEC1 < -2 818 molecules/cell (OR 4.16, percentiles as cut-off criteria) and 50.0% of patients with a Δ SIGLEC1 < -1 370 molecules/cell (OR 3.55, application of Youden index) showed clinical improvement. SIGLEC1 expression correlates inversely with the amount of therapeutically applied hydroxychloroquine (p < 0.001). Conclusions SIGLEC1 expression on monocytes is a sensitive biomarker for adjusting disease activity in childhood SLE and represents a promising and easily applicable tool for disease monitoring.

Download Full-text